Adaptimmune Net Borrowings vs Begin Period Cash Flow Analysis

ADAP Stock  USD 0.73  0.05  7.35%   
Adaptimmune Therapeutics financial indicator trend analysis is way more than just evaluating Adaptimmune Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Adaptimmune Therapeutics is a good investment. Please check the relationship between Adaptimmune Therapeutics Net Borrowings and its Begin Period Cash Flow accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adaptimmune Therapeutics Plc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

Net Borrowings vs Begin Period Cash Flow

Net Borrowings vs Begin Period Cash Flow Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Adaptimmune Therapeutics Net Borrowings account and Begin Period Cash Flow. At this time, the significance of the direction appears to have almost no relationship.
The correlation between Adaptimmune Therapeutics' Net Borrowings and Begin Period Cash Flow is 0.19. Overlapping area represents the amount of variation of Net Borrowings that can explain the historical movement of Begin Period Cash Flow in the same time period over historical financial statements of Adaptimmune Therapeutics Plc, assuming nothing else is changed. The correlation between historical values of Adaptimmune Therapeutics' Net Borrowings and Begin Period Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Borrowings of Adaptimmune Therapeutics Plc are associated (or correlated) with its Begin Period Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Begin Period Cash Flow has no effect on the direction of Net Borrowings i.e., Adaptimmune Therapeutics' Net Borrowings and Begin Period Cash Flow go up and down completely randomly.

Correlation Coefficient

0.19
Relationship DirectionPositive 
Relationship StrengthInsignificant

Net Borrowings

The difference between the amount of new debt a company has taken on and the amount of debt it has paid off during a given period.

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.
Most indicators from Adaptimmune Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Adaptimmune Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adaptimmune Therapeutics Plc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
As of 11/28/2024, Selling General Administrative is likely to drop to about 37.2 M. In addition to that, Tax Provision is likely to drop to about 832.7 K
 2021 2022 2023 2024 (projected)
Net Interest Income1.1M1.5M6.0M6.3M
Interest Income1.1M1.5M6.0M6.3M

Adaptimmune Therapeutics fundamental ratios Correlations

0.260.610.770.63-0.38-0.60.60.630.660.390.960.150.830.590.710.790.630.470.990.770.2-0.790.180.510.83
0.260.7-0.040.440.22-0.430.16-0.110.45-0.010.150.110.340.340.460.440.450.330.20.310.120.030.040.35-0.01
0.610.70.170.7-0.17-0.650.660.380.730.20.470.360.680.610.580.70.740.610.540.660.2-0.420.220.670.24
0.77-0.040.170.12-0.25-0.010.340.530.260.620.85-0.310.38-0.050.330.34-0.01-0.070.810.290.49-0.780.21-0.020.99
0.630.440.70.12-0.02-0.960.670.180.930.180.420.580.940.810.770.890.860.920.520.94-0.22-0.47-0.170.940.23
-0.380.22-0.17-0.25-0.020.11-0.11-0.870.080.07-0.46-0.29-0.22-0.310.09-0.06-0.3-0.13-0.45-0.26-0.240.46-0.8-0.09-0.27
-0.6-0.43-0.65-0.01-0.960.11-0.54-0.19-0.840.04-0.41-0.67-0.91-0.92-0.71-0.89-0.93-0.93-0.5-0.930.360.330.13-0.91-0.14
0.60.160.660.340.67-0.11-0.540.310.750.460.460.210.670.440.590.660.520.550.520.630.11-0.580.060.570.41
0.63-0.110.380.530.18-0.87-0.190.310.160.270.680.260.420.30.080.240.340.220.680.430.52-0.750.730.250.56
0.660.450.730.260.930.08-0.840.750.160.340.440.320.860.660.820.940.710.750.540.83-0.14-0.51-0.20.810.34
0.39-0.010.20.620.180.070.040.460.270.340.37-0.210.28-0.240.20.18-0.150.050.370.20.54-0.680.040.140.6
0.960.150.470.850.42-0.46-0.410.460.680.440.370.050.680.440.560.60.470.290.990.620.31-0.780.280.310.89
0.150.110.36-0.310.58-0.29-0.670.210.260.32-0.210.050.560.62-0.010.350.640.850.110.67-0.18-0.120.180.76-0.16
0.830.340.680.380.94-0.22-0.910.670.420.860.280.680.560.80.740.910.840.870.750.99-0.07-0.66-0.010.880.5
0.590.340.61-0.050.81-0.31-0.920.440.30.66-0.240.440.620.80.680.790.980.80.520.82-0.39-0.23-0.030.780.05
0.710.460.580.330.770.09-0.710.590.080.820.20.56-0.010.740.680.840.690.480.620.65-0.21-0.41-0.320.550.36
0.790.440.70.340.89-0.06-0.890.660.240.940.180.60.350.910.790.840.810.740.690.87-0.21-0.48-0.140.760.43
0.630.450.74-0.010.86-0.3-0.930.520.340.71-0.150.470.640.840.980.690.810.840.560.86-0.27-0.30.030.830.09
0.470.330.61-0.070.92-0.13-0.930.550.220.750.050.290.850.870.80.480.740.840.380.92-0.23-0.36-0.040.960.08
0.990.20.540.810.52-0.45-0.50.520.680.540.370.990.110.750.520.620.690.560.380.690.26-0.780.250.40.86
0.770.310.660.290.94-0.26-0.930.630.430.830.20.620.670.990.820.650.870.860.920.69-0.1-0.610.030.910.42
0.20.120.20.49-0.22-0.240.360.110.52-0.140.540.31-0.18-0.07-0.39-0.21-0.21-0.27-0.230.26-0.1-0.510.61-0.120.46
-0.790.03-0.42-0.78-0.470.460.33-0.58-0.75-0.51-0.68-0.78-0.12-0.66-0.23-0.41-0.48-0.3-0.36-0.78-0.61-0.51-0.33-0.43-0.81
0.180.040.220.21-0.17-0.80.130.060.73-0.20.040.280.18-0.01-0.03-0.32-0.140.03-0.040.250.030.61-0.33-0.050.21
0.510.350.67-0.020.94-0.09-0.910.570.250.810.140.310.760.880.780.550.760.830.960.40.91-0.12-0.43-0.050.11
0.83-0.010.240.990.23-0.27-0.140.410.560.340.60.89-0.160.50.050.360.430.090.080.860.420.46-0.810.210.11
Click cells to compare fundamentals

Adaptimmune Therapeutics Account Relationship Matchups

Adaptimmune Therapeutics fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets181.5M451.1M469.5M328.9M282.6M268.1M
Other Current Liab23.4M24.3M27.6M30.8M23.5M20.5M
Total Current Liabilities34.3M39.1M62.5M64.5M72.8M44.6M
Total Stockholder Equity123.6M341.2M206.0M81.9M39.5M37.5M
Property Plant And Equipment Net51.9M46.7M51.4M71.5M71.7M75.3M
Net Debt(25.0M)(33.2M)(124.5M)(85.0M)(118.8M)(112.8M)
Retained Earnings(455.7M)(585.8M)(743.8M)(909.3M)(1.0B)(972.0M)
Accounts Payable6.4M6.4M8.1M4.8M8.1M5.5M
Cash50.4M56.9M149.9M108.0M144.0M112.8M
Non Current Assets Total61.1M53.0M54.1M73.5M75.1M39.1M
Other Assets7.0M4.6M1.7M1.6M1.8M1.7M
Cash And Short Term Investments89.5M368.2M369.6M204.6M146.9M202.8M
Net Receivables(1.5M)139K752K7.4M46.9M49.3M
Common Stock Total Equity939K943K1.3M1.3M1.5M1.6M
Liabilities And Stockholders Equity181.5M451.1M469.5M328.9M282.6M268.1M
Non Current Liabilities Total23.6M70.8M201.0M182.5M170.3M178.8M
Other Current Assets30.9M34.0M54.2M51.5M13.7M21.1M
Other Stockholder Equity585.6M935.7M959.6M990.7M1.1B535.2M
Total Liab57.9M109.9M263.6M247.0M243.1M255.3M
Property Plant And Equipment Gross51.9M46.7M51.4M71.5M130.9M137.5M
Total Current Assets120.5M398.2M415.5M255.4M207.6M229.0M
Accumulated Other Comprehensive Income(7.3M)(10.0M)(11.1M)(875K)(3.7M)(3.6M)
Common Stock943K1.3M1.3M1.4M1.9M2.0M
Short Long Term Debt Total25.5M23.7M25.5M23.1M25.2M38.5M
Common Stock Shares Outstanding105.0M142.5M155.8M161.2M201.1M129.5M
Property Plant Equipment31.1M27.8M30.5M71.5M82.3M86.4M
Net Tangible Assets121.4M339.5M205.0M81.4M93.7M89.0M
Non Currrent Assets Other7.0M4.6M1.7M1.6M3.0M3.6M
Short Term Investments39.1M311.3M219.6M96.6M2.9M2.8M
Other Liab598K49.9M177.9M162.2M186.5M195.8M
Inventory1.5M2.1M746K1.3M1.3M1.4M
Intangible Assets2.2M1.7M1M442K330K313.5K
Capital Surpluse574.2M585.6M935.7M959.6M1.1B657.5M
Retained Earnings Total Equity(318.5M)(455.7M)(585.8M)(743.8M)(669.5M)(636.0M)
Non Current Liabilities Other23.6M70.8M201.0M1.3M1.4M1.3M
Net Invested Capital123.6M341.2M206.0M81.9M39.5M37.5M
Net Working Capital86.1M359.1M352.9M190.9M134.8M233.6M
Capital Stock943K1.3M1.3M1.4M1.9M1.4M

Pair Trading with Adaptimmune Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Adaptimmune Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Adaptimmune Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Adaptimmune Stock

  0.89FDMT 4D Molecular TherapeuticsPairCorr
  0.76JNJ Johnson Johnson Fiscal Year End 28th of January 2025 PairCorr
  0.88MRK Merck Company Fiscal Year End 6th of February 2025 PairCorr

Moving against Adaptimmune Stock

  0.83BMY Bristol Myers Squibb Aggressive PushPairCorr
  0.73NAMS NewAmsterdam PharmaPairCorr
  0.59PHVS Pharvaris BVPairCorr
  0.48ESLAW Estrella ImmunopharmaPairCorr
  0.46PMVP Pmv PharmaceuticalsPairCorr
The ability to find closely correlated positions to Adaptimmune Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Adaptimmune Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Adaptimmune Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Adaptimmune Therapeutics Plc to buy it.
The correlation of Adaptimmune Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Adaptimmune Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Adaptimmune Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Adaptimmune Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Adaptimmune Stock Analysis

When running Adaptimmune Therapeutics' price analysis, check to measure Adaptimmune Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptimmune Therapeutics is operating at the current time. Most of Adaptimmune Therapeutics' value examination focuses on studying past and present price action to predict the probability of Adaptimmune Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptimmune Therapeutics' price. Additionally, you may evaluate how the addition of Adaptimmune Therapeutics to your portfolios can decrease your overall portfolio volatility.